Overview

Tyrosine kinase, non-receptor, 2 (TNK2) is a gene that encodes a protein that inhibits the intrinsic and GTPase-activating protein (GAP)-stimulated GTPase activity of Cdc42Hs. Missense mutations, silent mutations, frameshift deletions, nonsense mutations, and frameshift insertions are observed in cancers such as colon cancer, skin cancer, and eye cancer.

TNK2 is altered in 4.58% of all cancers with endometrial endometrioid adenocarcinoma, high grade ovarian serous adenocarcinoma, breast invasive ductal carcinoma, low grade ovarian serous adenocarcinoma, and cervical squamous cell carcinoma having the greatest prevalence of alterations [3].

The most common alterations in TNK2 are TNK2 T750P (2.08%), TNK2 L589Q (0.70%), TNK2 G723S (0.28%), TNK2 I745L (1.17%), and TNK2 A677V (0.22%) [3].

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.